Ethical issues in including pediatric cancer patients in drug development trials

Pediatric Drugs

Volumn 4, Issue 4, 2002, Pages 257-265

  Aleksa, K ^a,b   Koren, G ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; DOSE CALCULATION; DRUG RESEARCH; ETHICS; HUMAN; MEDICAL DECISION MAKING; MORALITY; PEDIATRICS; PRIORITY JOURNAL; REVIEW;

EID: 0036257540     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204040-00005     Document Type: Review

References (38)

1. Cancer statistics, 1998
2. How common is childhood cancer?
3. Cancer statistics, 1999
4. A conspiracy of cells
5. The impact of childhood cancer on the United States and the world
6. The relationship between ethics and science in pediatric research
7. Principles of clinical trial design
8. An overview of clinical trials in oncology
9. The importance of clinical trials
10. Randomized clinical trials: Perspectives on some recent ideas
11. Informed consent in pediatric research
12. Children as participants in medical research
13. Clinical trial design and alterations in drug disposition with age
14. Off-label uses of drugs in children
15. The thalidomide tragedy in Germany: The end of a historic medicolegal trial
16. A study of the German outbreak of phocomelia
17. Differences between children and adults
18. Pediatric trials: Practical issues. Special populations and trial design
19. Medical research in children
20. Informed consent in the childrens cancer group: Results of preliminary research
21. Clinical research and clinical care: Ethical problems in the 'war on cancer'
22. Children as decision makers: Guidelines for pediatricians
23. Empirical examination of the ability of children to consent to clinical research
24. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma
25. Ifosfamide nephrotoxicity in paediatric cancer patients
26. Renal function abnormalities after ifosfamide treatment in children
27. Progressive renal toxicity due to ifosfamide
28. Ifosfamide with mesna uroprotection in the management of lung cancer
29. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy
30. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children
31. Risk factors for ifosfamide nephrotoxicity in children
32. Research in children: Issues of risk and harm
33. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations
34. Clinical trials in pediatric oncology